322 Shares in Zoetis Inc. (NYSE:ZTS) Acquired by Frazier Financial Advisors LLC

Frazier Financial Advisors LLC purchased a new stake in Zoetis Inc. (NYSE:ZTS) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 322 shares of the company’s stock, valued at approximately $64,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of ZTS. Cary Street Partners Investment Advisory LLC boosted its position in shares of Zoetis by 7.4% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 93,735 shares of the company’s stock worth $16,308,000 after purchasing an additional 6,457 shares in the last quarter. Peak Financial Advisors LLC bought a new position in Zoetis in the fourth quarter worth approximately $2,776,000. Ninety One UK Ltd grew its stake in Zoetis by 13.1% in the fourth quarter. Ninety One UK Ltd now owns 108,293 shares of the company’s stock valued at $21,374,000 after acquiring an additional 12,537 shares during the period. Raymond James Financial Services Advisors Inc. increased its holdings in shares of Zoetis by 10.9% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 183,564 shares of the company’s stock valued at $36,230,000 after acquiring an additional 17,976 shares in the last quarter. Finally, Fiera Capital Corp raised its position in shares of Zoetis by 13.9% during the fourth quarter. Fiera Capital Corp now owns 558,492 shares of the company’s stock worth $110,230,000 after purchasing an additional 68,146 shares during the period. 92.80% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

ZTS has been the subject of several research reports. HSBC reduced their price target on shares of Zoetis from $230.00 to $225.00 and set a “buy” rating for the company in a research report on Wednesday, May 8th. The Goldman Sachs Group reduced their price objective on shares of Zoetis from $223.00 to $196.00 and set a “buy” rating for the company in a report on Monday, May 6th. Barclays lowered their target price on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a report on Tuesday, April 23rd. Piper Sandler reiterated an “overweight” rating and set a $195.00 price target (down previously from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. Finally, StockNews.com downgraded Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Zoetis currently has a consensus rating of “Buy” and a consensus target price of $211.75.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of the stock in a transaction dated Thursday, April 18th. The shares were sold at an average price of $151.17, for a total transaction of $139,529.91. Following the completion of the transaction, the executive vice president now owns 14,800 shares in the company, valued at $2,237,316. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.16% of the company’s stock.

Zoetis Stock Performance

NYSE:ZTS traded up $0.33 during trading on Thursday, reaching $172.38. The company’s stock had a trading volume of 922,318 shares, compared to its average volume of 3,053,654. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $201.92. The firm has a market cap of $78.66 billion, a price-to-earnings ratio of 33.15, a price-to-earnings-growth ratio of 2.68 and a beta of 0.86. The firm has a 50 day moving average of $164.22 and a 200-day moving average of $179.63. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.94 and a current ratio of 3.33.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, May 2nd. The company reported $1.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.34 by $0.04. The business had revenue of $2.19 billion during the quarter, compared to the consensus estimate of $2.14 billion. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. The firm’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same quarter last year, the company posted $1.31 earnings per share. Research analysts expect that Zoetis Inc. will post 5.77 EPS for the current fiscal year.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.